JP2022524814A5 - - Google Patents
Info
- Publication number
- JP2022524814A5 JP2022524814A5 JP2021554699A JP2021554699A JP2022524814A5 JP 2022524814 A5 JP2022524814 A5 JP 2022524814A5 JP 2021554699 A JP2021554699 A JP 2021554699A JP 2021554699 A JP2021554699 A JP 2021554699A JP 2022524814 A5 JP2022524814 A5 JP 2022524814A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- concentration
- lingo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816668P | 2019-03-11 | 2019-03-11 | |
| US62/816,668 | 2019-03-11 | ||
| US201962817323P | 2019-03-12 | 2019-03-12 | |
| US62/817,323 | 2019-03-12 | ||
| PCT/US2020/021842 WO2020185750A1 (en) | 2019-03-11 | 2020-03-10 | Pharmaceutical compositions containing anti-lingo-1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022524814A JP2022524814A (ja) | 2022-05-10 |
| JP2022524814A5 true JP2022524814A5 (https=) | 2023-03-17 |
Family
ID=70190131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554699A Pending JP2022524814A (ja) | 2019-03-11 | 2020-03-10 | 抗ｌｉｎｇｏ－１抗体を含む医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220144945A1 (https=) |
| EP (1) | EP3938395A1 (https=) |
| JP (1) | JP2022524814A (https=) |
| KR (1) | KR20210136063A (https=) |
| CN (1) | CN113661179A (https=) |
| AU (1) | AU2020234943A1 (https=) |
| BR (1) | BR112021017644A2 (https=) |
| CA (1) | CA3133072A1 (https=) |
| IL (1) | IL286162A (https=) |
| MA (1) | MA55298A (https=) |
| MX (1) | MX2021010420A (https=) |
| TW (1) | TW202103732A (https=) |
| UY (1) | UY38605A (https=) |
| WO (1) | WO2020185750A1 (https=) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen, Inc. | Rekombinante anti-vla4 antikörpermoleküle |
| ATE161730T1 (de) | 1993-02-09 | 1998-01-15 | Biogen Inc | Antikörper zur behandlung von insulinabhängigen diabetes |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| CA2519227C (en) | 2003-03-19 | 2013-12-03 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| US8486893B2 (en) | 2004-06-24 | 2013-07-16 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| KR20190039134A (ko) * | 2016-07-13 | 2019-04-10 | 바이오젠 엠에이 인코포레이티드 | Lingo-1 길항제의 투약 섭생 및 탈수초성 질환의 치료를 위한 용도 |
| JP7382232B2 (ja) * | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| CN118370815A (zh) * | 2017-08-22 | 2024-07-23 | 渤健马萨诸塞州股份有限公司 | 含有抗β淀粉样蛋白抗体的药物组合物 |
-
2020
- 2020-03-10 MA MA055298A patent/MA55298A/fr unknown
- 2020-03-10 US US17/437,634 patent/US20220144945A1/en not_active Abandoned
- 2020-03-10 CA CA3133072A patent/CA3133072A1/en active Pending
- 2020-03-10 JP JP2021554699A patent/JP2022524814A/ja active Pending
- 2020-03-10 AU AU2020234943A patent/AU2020234943A1/en not_active Abandoned
- 2020-03-10 TW TW109107890A patent/TW202103732A/zh unknown
- 2020-03-10 BR BR112021017644A patent/BR112021017644A2/pt not_active Application Discontinuation
- 2020-03-10 CN CN202080027211.8A patent/CN113661179A/zh active Pending
- 2020-03-10 UY UY0001038605A patent/UY38605A/es not_active Application Discontinuation
- 2020-03-10 KR KR1020217031856A patent/KR20210136063A/ko not_active Withdrawn
- 2020-03-10 EP EP20717406.1A patent/EP3938395A1/en not_active Withdrawn
- 2020-03-10 WO PCT/US2020/021842 patent/WO2020185750A1/en not_active Ceased
- 2020-03-10 MX MX2021010420A patent/MX2021010420A/es unknown
-
2021
- 2021-09-05 IL IL286162A patent/IL286162A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12497436B2 (en) | Chimeric protein, and encoding nucleic acid thereof, comprising interferon-β and a targeting moiety comprising a single-domain antibody or single-chain antibody | |
| JP5823954B2 (ja) | Ｆｇｆ２１変異体及びその使用 | |
| AU2015370522B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
| JP2023517236A5 (https=) | ||
| US20220259308A1 (en) | Fcrn antibodies and methods of use thereof | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP2021533204A5 (https=) | ||
| JP2024102205A5 (https=) | ||
| AU2015313827C1 (en) | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| KR20200017421A (ko) | 항-trkb 항체 | |
| KR20250084991A (ko) | 항-FcRN 항체를 이용한 만성 염증성 탈수초성 다발성 신경병증의 치료 방법 | |
| JP2026009900A (ja) | 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ | |
| CN118355025A (zh) | 肥大细胞相关障碍的治疗 | |
| JP2024507118A5 (https=) | ||
| WO2023009975A2 (en) | Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications | |
| EP4376870A1 (en) | Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications | |
| JP2022524814A5 (https=) | ||
| WO2017221174A1 (en) | Methods of treating vitiligo using interleukin-17 (il-17) antibodies | |
| JP2020531521A5 (https=) | ||
| JP2025519612A (ja) | Ｉｇｆ１ｒ抗体 | |
| RU2021129295A (ru) | Фармацевтические композиции, содержащие антитела к lingo-1 | |
| US20220378925A1 (en) | Conjugated chimeric proteins | |
| CN119095618B (zh) | 用于治疗巨噬细胞活化综合征的组合物和方法 | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 |